SCHEMBL2826322

SCHEMBL2826322

N#Cc1ccc(Oc2cc(Cl)cc(Cl)c2)c(S(=O)(=O)N2CCCC2N)c1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 8/20 0.42
EPAS1 Q99814 9/20 0.39
VEGFA P15692 3/20 0.39
TRPC6 Q9Y210 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
DPP4 P27487 1/20 0.36
PREP P48147 1/20 0.36
FAP Q12884 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
DPP7 Q9UHL4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2820385 0.99 TBXA2R (0.42) TBXA2REPAS1VEGFATRPC6ALDH1A1
SCHEMBL2821883 0.85 HRH3 (0.39) TBXA2REPAS1VEGFAALDH1A1KMT2A
SCHEMBL2821885 0.85 HRH3 (0.39) TBXA2REPAS1VEGFAALDH1A1KMT2A
SCHEMBL2379501 0.85 ALDH1A1 (0.43) TBXA2REPAS1VEGFATRPC6ALDH1A1
SCHEMBL2819981 0.83 TRPV4 (0.40) TBXA2REPAS1VEGFATRPC6ALDH1A1
SCHEMBL2819983 0.83 TRPV4 (0.40) TBXA2REPAS1VEGFATRPC6ALDH1A1
SCHEMBL3125059 0.83 TBXA2R (0.42) TBXA2REPAS1VEGFAALDH1A1KMT2A
SCHEMBL3123218 0.83 TBXA2R (0.41) TBXA2REPAS1VEGFA
SCHEMBL13617366 0.82 SPHK2 (0.42) TBXA2REPAS1VEGFA
SCHEMBL13630672 0.82 TBXA2R (0.38) TBXA2REPAS1VEGFAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1849469-B1 Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS INC (US) 2010-10-27 EP disclosed
EP-1461038-B9 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS ACTIMIS PHARMACEUTICALS INC (US) 2009-09-23 EP disclosed
EP-1849469-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS Actimis Pharmaceuticals, Inc., (US) 2007-10-31 EP disclosed
EP-1461038-B1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS ACTIMIS PHARMACEUTICALS INC (US) 2007-08-01 EP disclosed